Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole withdrawal study in infants with GERD
2008-004847-12Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rabeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline to end of study in I-GERQ-R total score, Change from baseline to end of study in I-GERQ-DD total score and 3 more. Started Sep 2009; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2008-004847-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004847-12.